Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial-Reference-Cited by-同舟云学术

Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial

Published:2023-10 Issue:10 Volume:11 Page:894-904
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

François Bruno,Lambden Simon,Fivez Tom,Gibot Sebastien,Derive Marc,Grouin Jean-Marie,Salcedo-Magguilli Margarita,Lemarié Jérémie,De Schryver Nicolas,Jalkanen Ville,Hicheur Tarik,Garaud Jean-Jacques,Cuvier Valérie,Ferrer Ricard,Bestle Morten,Pettilä Ville,Mira Jean-Paul,Bouisse Camille,Mercier Emmanuelle,Vermassen Joris,Huberlant Vincent,Vinatier Isabelle,Anguel Nadia,Levy Mitchell,Laterre Pierre-François,Asfar Pierre,Nay Mai-Anh,Guitton Christophe,Quenot Jean-Pierre,Tran-Van David,Bohe Julien,Plantefève Gaëtan,Nseir Saadalla,Lefrant Jean-Yves,Monnet Xavier,Papazian Laurent,Vinsonneau Christophe,Constantin Jean-Michel,Mebazaa Alexandre,Oueslati Haikel,Escudero Dolores,Martinez Sagasti Fernando,Piacentini Enrique,Ramirez Galleymore Paula,Dugernier Thierry,Fagnoul David,Michaux Isabelle,Seibert Allan,Reinikainen Matti,Grøfte Thorbjørn,Martin-Loeches Ignacio,Laffey John

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference23 articles.

1. The third international consensus definitions for sepsis and septic shock (sepsis-3);Singer;JAMA,2016

2. Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (sepsis-3);Shankar-Hari;JAMA,2016

3. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021;Evans;Intensive Care Med,2021

4. The next generation of sepsis clinical trial designs: what's next after the demise of recombinant human activated protein C?;Opal;Crit Care Med,2014

5. The search for effective therapy for sepsis: back to the drawing board?;Angus;JAMA,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding, assessing and treating immune, endothelial and haemostasis dysfunctions in bacterial sepsis;Intensive Care Medicine;2024-09-02

2. Sepsis in 2024: A Review;Anaesthesia & Intensive Care Medicine;2024-08

3. Enhancing sepsis biomarker development: key considerations from public and private perspectives;Critical Care;2024-07-13

4. Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment;International Journal of Molecular Sciences;2024-07-05

5. Acute Management of Sepsis beyond 24 Hours;Seminars in Respiratory and Critical Care Medicine;2024-07-05